Based on the discussion with the FDA.

The Company also offers a Marketing Authorisation Software under critique with the European Medications Agency for CML sufferers who’ve failed imatinib and have the T315I mutation. This review can be on the right track, with a potential acceptance in Europe in the first quarter of 2011. The up to date corporate overview for ChemGenex is definitely on the company’s website.. ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML ChemGenex Pharmaceuticals Small announced today it has agreed with the U.S. Based on the discussion with the FDA, ChemGenex intends to mix data from its two pivotal studies, Study 202 and Study 203, and send a New Drug Application for OMAPRO for all those patients with CML who have failed prior treatment with two or more currently approved tyrosine kinase inhibitors .The scholarly study, released in GIE: Gastrointestinal Endoscopy, implies that these devices, which acts just like the well-known clothespin-type finger clip utilized to measure bloodstream oxygen in patients, includes a sensitivity of 92 % and a specificity of 86 %. MULTIMEDIA ALERT: Video and audio are for sale to download on the Mayo Clinic Information Network. Which means, of 100 individuals with pancreatic cancers, this sensor would detect 92 of these, based on the results. And of 100 individuals who don't have pancreatic cancer, the check would correctly identify them 86 % of that time period.